ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Antihypertensive drugs and lipids

Antihypertensive drugs and lipids
Literature review current through: May 2024.
This topic last updated: Feb 12, 2024.

INTRODUCTION — Drug-induced changes in lipid levels may be particularly important in hypertensive patients since up to 45 percent of untreated patients with primary hypertension (formerly called "essential" hypertension) already have lipid abnormalities, such as an elevated low-density lipoprotein (LDL) cholesterol [1]. In addition, genetic studies in humans suggest that a predisposition for the development of both hypertension and dyslipidemia may result from the inheritance of shared genetic risk factors [2].

In general, effects of blood pressure-lowering agents on lipid levels and effects of statins on blood pressure are modest. Blood pressure lowering and lipid lowering provide independent and additive reductions in cardiovascular risk [3,4] and may provide a high absolute benefit in individuals with multiple cardiovascular risk factors [5].

This topic will address the effects of antihypertensive medications on serum lipids and the effects of cholesterol lowering medications on blood pressure. The management of adults with hypertension, a review of established risk factors for cardiovascular disease, and cardiovascular disease risk assessment are discussed elsewhere. (See "Goal blood pressure in adults with hypertension" and "Overview of established risk factors for cardiovascular disease" and "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach" and "Cardiovascular disease risk assessment for primary prevention: Risk calculators".)

EFFECTS OF DIFFERENT ANTIHYPERTENSIVE AGENTS — Treatment of hypertension can affect lipid levels. Some antihypertensive drugs, for example, have a neutral or beneficial effect on the lipid profile, while others have an adverse effect; such adverse effects are outweighed by the beneficial clinical effects of blood pressure lowering on cardiovascular risk.

Antihypertensive drugs with adverse effects on plasma lipid levels — Thiazide diuretics and beta blockers may adversely affect lipid levels. However, we would not avoid using these medications (if otherwise indicated) in a patient with dyslipidemia, and, similarly, we would not discontinue these medications in a patient just to improve the lipid profile [6].

Thiazide diuretics — High doses of thiazide diuretics (50 to 100 mg of hydrochlorothiazide or chlorthalidone in one study) produce an initial 5 to 10 percent elevation in total and low-density lipoprotein (LDL) cholesterol and a lesser increase in triglycerides [7]. The hyperlipidemic effect of thiazide diuretics is dose dependent [7,8]; contemporary doses lead to more modest lipid effects. As an example, there is little or no effect on lipid metabolism with hydrochlorothiazide 12.5 mg daily or its equivalent [9], a dose that may have an antihypertensive effect nearly as great as higher doses (see "Use of thiazide diuretics in patients with primary (essential) hypertension"). In addition, in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), chlorthalidone 25 mg produced a slightly higher mean total cholesterol than did lisinopril 40 mg or amlodipine 10 mg at four years, but the mean difference was <2.5 mg/dL [10].

Beta blockers — Beta blockers are a heterogeneous class of antihypertensive medications. The effect of beta blockers on serum lipids varies with their unique pharmacologic characteristics and may be more prominent among smokers [8,11].

Many traditional beta blockers, both cardioselective and noncardioselective (such as atenolol, metoprolol, and propranolol), lead to a fairly modest increase in triglycerides (20 to 40 percent), a decrease in high-density lipoprotein (HDL) cholesterol (approximately 10 percent), and little effect on total cholesterol or LDL cholesterol [8,12]. By contrast, labetalol (a combined alpha and beta blocker) as well as beta blockers with intrinsic sympathomimetic activity (eg, acebutolol and pindolol) have relatively little impact on lipid levels due to a favorable effect on lipoprotein lipase [8].

Vasodilating beta blockers have a more favorable metabolic profile. Carvedilol, a combined nonselective beta and alpha-1 blocker, has less of a deleterious effect on triglyceride levels than metoprolol or atenolol [13,14], and nebivolol appears to have a neutral effect [15]. (See "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'.)

Antihypertensive drugs with neutral or beneficial effects on plasma lipid levels — Other than thiazide diuretics and beta blockers, antihypertensive medications generally have a neutral or beneficial effect on the lipid profile [16]. However, we do not consider these effects when choosing antihypertensive therapy.

Angiotensin-converting enzyme inhibitors — The angiotensin-converting enzyme inhibitors appear to have no significant effect on plasma lipids [8] and may minimize or prevent the rise in lipids induced by diuretic therapy (via an unknown mechanism) [17].

Angiotensin receptor blockers — In most clinical studies, angiotensin receptor blockers had either a neutral or modest beneficial effect on lipid levels [18,19].

Calcium channel blockers — The calcium channel blockers appear to have either a neutral or mildly beneficial effect on the lipid profile [8].

Alpha blockers — The selective alpha-1 blockers, specifically prazosin, doxazosin, and terazosin, improve lipoprotein lipase activity and consistently demonstrate favorable effects on plasma lipids. These drugs lower total cholesterol by approximately 3 to 5 percent, reduce triglyceride levels by 3 to 4 percent, and mildly raise HDL cholesterol; the clinical significance of these changes is unclear [8,20].

Sympathetic blockers — The effect of the centrally acting sympathetic inhibitors, methyldopa, clonidine, and guanabenz, on the lipid profile has not been well studied. Both favorable and detrimental changes have been reported. On average, there is little, if any, change in lipid levels [8].

Effects of combination therapy — The effect of combination therapy in most cases appears to reflect the sum of the effect of the individual drugs [8].

EFFECT OF STATINS ON BLOOD PRESSURE — Treatment of dyslipidemia with statins may independently lower blood pressure, although the effect is modest [21,22]. This was demonstrated in the University of California San Diego (UCSD) Statin Effects Study, which randomly assigned 973 individuals to 20 mg of simvastatin, 40 mg of pravastatin, or placebo [23]. At six months, both statins modestly reduced systolic and diastolic blood pressure by 2.2 and 2.4 mmHg, respectively. Similarly, in a meta-analysis of 49 randomized trials involving over 45,000 participants, mean systolic and diastolic blood pressure was lower by 1.42 mmHg and 0.82 mmHg, respectively, in patients receiving statin therapy when compared with placebo [24]. Nonstatin lipid-lowering medications have not been reported to have any notable effects on blood pressure.

SUMMARY

Overview – Treatment of hypertension can affect lipid levels, and treatment of dyslipidemia with statins can affect blood pressure. In general, effects of blood pressure-lowering agents on lipid levels and effects of statins on blood pressure are modest. Blood pressure lowering and lipid lowering provide independent and additive reductions in cardiovascular risk.

Thiazide diuretics and beta blockers – Thiazide diuretics (at doses higher than typically used) and some beta blockers (particularly atenolol, metoprolol, and propranolol) may adversely affect lipid levels. However, we would not discontinue or avoid using these medications in a patient with dyslipidemia, as these effects are outweighed by the beneficial clinical effects of blood pressure lowering on cardiovascular risk. (See 'Antihypertensive drugs with adverse effects on plasma lipid levels' above.)

Other antihypertensive drugs – Most other antihypertensive medications, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and alpha blockers, have a neutral or beneficial effect on the lipid profile. However, we do not consider these effects when choosing antihypertensive therapy. (See 'Antihypertensive drugs with neutral or beneficial effects on plasma lipid levels' above.)

Statins and blood pressure – Treatment of dyslipidemia with statins may independently lower blood pressure, although the effect is modest. (See 'Effect of statins on blood pressure' above.)

ACKNOWLEDGMENT — The editorial staff at UpToDate acknowledge Norman M Kaplan, MD, who contributed to an earlier version of this topic review.

  1. Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation 2013; 128:29.
  2. Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988; 259:3579.
  3. Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27:2982.
  4. Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016; 374:2032.
  5. Williams B, Masi S, Wolf J, Schmieder RE. Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. Cardiol Ther 2020; 9:19.
  6. Mänttäri M, Tenkanen L, Manninen V, et al. Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality. Hypertension 1995; 25:47.
  7. Grimm RH Jr, Leon AS, Hunninghake DB, et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 1981; 94:7.
  8. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.
  9. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8:461.
  10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.
  11. Vyssoulis GP, Karpanou EA, Pitsavos CE, et al. Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension. Am J Cardiol 1991; 67:987.
  12. Wolinsky H. The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987; 10:561.
  13. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955.
  14. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.
  15. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8:127.
  16. Kannel WB, Carter BL. Initial drug therapy for hypertensive patients with hyperlipidemia. Am Heart J 1989; 118:1012.
  17. Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5:III132.
  18. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27:457.
  19. Kirk JK. Angiotensin-II receptor antagonists: their place in therapy. Am Fam Physician 1999; 59:3140.
  20. Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131:966.
  21. Spósito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83:1497.
  22. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30:980.
  23. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168:721.
  24. Liu HT, Deng NH, Wu ZF, et al. Statin's role on blood pressure levels: Meta-analysis based on randomized controlled trials. J Clin Hypertens (Greenwich) 2023; 25:238.
Topic 3867 Version 27.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟